Smoking status-based efficacy difference in anti-PD-1/PD-L1 immunotherapy: a systematic review and meta-analysis

被引：9
作者：
Nie, Run-Cong [1 ]
Duan, Shu-Qiang YuanJin-Ling [1 ,3 ]
Liang, Yao [1 ]
Chen, Xiao-Jiang [1 ]
Chen, Yong-Ming [1 ]
Luo, Tian-Qi [1 ]
Chen, Guo-Ming [1 ]
Wang, Yun [2 ]
Li, Yuan-Fang [1 ]
机构：
[1] Sun Yat Sen Univ, Canc Ctr, State Key Lab Oncol South China, Dept Gastr Surg,Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Dept Hematol Oncol,Canc Ctr, Guangzhou, Peoples R China
[3] Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Canc Ctr, Guangzhou 510060, Peoples R China
来源：
IMMUNOTHERAPY | 2020年 / 12卷 / 18期
关键词：
efficacy; immunotherapy; overall survival; PD-1; PD-L1; smoking; OPEN-LABEL; CANCER-IMMUNOTHERAPY; CHOICE CHEMOTHERAPY; SOLID TUMORS; NIVOLUMAB; PEMBROLIZUMAB; DOCETAXEL; BLOCKADE; ATEZOLIZUMAB; MULTICENTER;
D O I：
10.2217/imt-2020-0007
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Aim:This study aimed to evaluate the relationship between smoking status and efficacy of PD-1/PD-L1 inhibitors compared with conventional agents.Materials & methods:We reviewed Phase II/III trials of PD-1/PD-L1 inhibitors that reported hazard ratio (HR) in current/former and never smoking patients.Results: 15 qualifying trials comprising 9073 patients were eligible in this study. Compared with conventional agents, PD-1/PD-L1 inhibitors correlated with prolonged progression-free survival (HR: 0.73; 0.58-0.92) and overall survival (HR: 0.75; 0.71-0.80) in current/former smoker patients but not in never-smoker patients (HR: 1.15 and 0.86 for progression-free survival and overall survival, respectively; both p > 0.05) irrespective of cancer type, target of experimental agents and treatment strategy.Conclusion:There exit smoking status-based efficacy difference in anti-PD-1/PD-L1 immunotherapy.
引用
收藏
页码：1313 / 1324
页数：12
相关论文
共 50 条
  • [1] Mutational signatures associated with tobacco smoking in human cancer
    Alexandrov, Ludmil B.
    Ju, Young Seok
    Haase, Kerstin
    Van Loo, Peter
    Martincorena, Inigo
    Nik-Zainal, Serena
    Totoki, Yasushi
    Fujimoto, Akihiro
    Nakagawa, Hidewaki
    Shibata, Tatsuhiro
    Campbell, Peter J.
    Vineis, Paolo
    Phillips, David H.
    Stratton, Michael R.
    [J]. SCIENCE, 2016, 354 (6312) : 618 - 622
  • [2] Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
    Antonia, S. J.
    Villegas, A.
    Daniel, D.
    Vicente, D.
    Murakami, S.
    Hui, R.
    Kurata, T.
    Chiappori, A.
    Lee, K. H.
    de Wit, M.
    Cho, B. C.
    Bourhaba, M.
    Quantin, X.
    Tokito, T.
    Mekhail, T.
    Planchard, D.
    Kim, Y. -C.
    Karapetis, C. S.
    Hiret, S.
    Ostoros, G.
    Kubota, K.
    Gray, J. E.
    Paz-Ares, L.
    Carpeno, J. de Castro
    Faivre-Finn, C.
    Reck, M.
    Vansteenkiste, J.
    Spigel, D. R.
    Wadsworth, C.
    Melillo, G.
    Taboada, M.
    Dennis, P. A.
    Ozguroglu, M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (24) : 2342 - 2350
  • [3] Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study
    Barlesi, Fabrice
    Vansteenkiste, Johan
    Spigel, David
    Ishii, Hidenobu
    Garassino, Marina
    de Marinis, Filippo
    Ozguroglu, Mustafa
    Szczesna, Aleksandra
    Polychronis, Andreas
    Uslu, Ruchan
    Krzakowski, Maciej
    Lee, Jong-Seok
    Calabro, Luana
    Frontera, Osvaldo Aren
    Ellers-Lenz, Barbara
    Bajars, Marcis
    Ruisi, Mary
    Park, Keunchil
    [J]. LANCET ONCOLOGY, 2018, 19 (11) : 1468 - 1479
  • [4] Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
    Bellmunt, J.
    de Wit, R.
    Vaughn, D. J.
    Fradet, Y.
    Lee, J. -L.
    Fong, L.
    Vogelzang, N. J.
    Climent, M. A.
    Petrylak, D. P.
    Choueiri, T. K.
    Necchi, A.
    Gerritsen, W.
    Gurney, H.
    Quinn, D. I.
    Culine, S.
    Sternberg, C. N.
    Mai, Y.
    Poehlein, C. H.
    Perini, R. F.
    Bajorin, D. F.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11) : 1015 - 1026
  • [5] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
    Borghaei, H.
    Paz-Ares, L.
    Horn, L.
    Spigel, D. R.
    Steins, M.
    Ready, N. E.
    Chow, L. Q.
    Vokes, E. E.
    Felip, E.
    Holgado, E.
    Barlesi, F.
    Kohlhaeufl, M.
    Arrieta, O.
    Burgio, M. A.
    Fayette, J.
    Lena, H.
    Poddubskaya, E.
    Gerber, D. E.
    Gettinger, S. N.
    Rudin, C. M.
    Rizvi, N.
    Crino, L.
    Blumenschein, G. R.
    Antonia, S. J.
    Dorange, C.
    Harbison, C. T.
    Finckenstein, F. Graf
    Brahmer, J. R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) : 1627 - 1639
  • [6] First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer
    Carbone, D. P.
    Reck, M.
    Paz-Ares, L.
    Creelan, B.
    Horn, L.
    Steins, M.
    Felip, E.
    van den Heuvel, M. M.
    Ciuleanu, T. -E.
    Badin, F.
    Ready, N.
    Hiltermann, T. J. N.
    Nair, S.
    Juergens, R.
    Peters, S.
    Minenza, E.
    Wrangle, J. M.
    Rodriguez-Abreu, D.
    Borghaei, H.
    Blumenschein, G. R.
    Villaruz, L. C.
    Havel, L.
    Krejci, J.
    Corral Jaime, J.
    Chang, H.
    Geese, W. J.
    Bhagavatheeswaran, P.
    Chen, A. C.
    Socinski, M. A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (25) : 2415 - 2426
  • [7] Elements of cancer immunity and the cancer-immune set point
    Chen, Daniel S.
    Mellman, Ira
    [J]. NATURE, 2017, 541 (7637) : 321 - 330
  • [8] Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
    Cohen, Ezra E. W.
    Soulieres, Denis
    Le Tourneau, Christophe
    Dinis, Jose
    Licitra, Lisa
    Ahn, Myung-Ju
    Soria, Ainara
    Machiels, Jean-Pascal
    Mach, Nicolas
    Mehra, Ranee
    Burtness, Barbara
    Zhang, Pingye
    Cheng, Jonathan
    Swaby, Ramona F.
    Harrington, Kevin J.
    [J]. LANCET, 2019, 393 (10167) : 156 - 167
  • [9] Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy
    Cristescu, Razvan
    Mogg, Robin
    Ayers, Mark
    Albright, Andrew
    Murphy, Erin
    Yearley, Jennifer
    Sher, Xinwei
    Liu, Xiao Qiao
    Lu, Hongchao
    Nebozhyn, Michael
    Zhang, Chunsheng
    Lunceford, Jared
    Joe, Andrew
    Cheng, Jonathan
    Webber, Andrea L.
    Ibrahim, Nageatte
    Plimack, Elizabeth R.
    Ott, Patrick A.
    Seiwert, Tanguy
    Ribas, Antoni
    McClanahan, Terrill K.
    Tomassini, Joanne E.
    Loboda, Andrey
    Kaufman, David
    [J]. SCIENCE, 2018, 362 (6411) : 197 - +
  • [10] Bias in meta-analysis detected by a simple, graphical test
    Egger, M
    Smith, GD
    Schneider, M
    Minder, C
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1997, 315 (7109): : 629 - 634
12345